Research: What was the value of Human Genome Science?
When Human Genome Sciences (HGS) was acquired by GlaxoSmithKline (GSK) in 2012, its “fair value” was $3.6B, less than the $3.9B capital investments in the company. Does this truly reflect the value of a product (BenlystaTM) with billion-dollar potential, HGS’ product pipeline, and >600 patents? A recent paper from the Center for Integration of Science and Industry reviews the history of HGS...
Research: Can newly-public biotech succeed at translational science? by Laura McNamee and Fred Ledley
Early-stage biotech companies play a critical role in the entrepreneurial ecosystem that is expected to develop commercial products from nascent scientific discoveries. Recent research from the Center for Integration of Science and Industry suggests that companies in the IPO “class of 2000” were ineffective in developing therapeutic products and asks whether the business models of newly-public...
Research: Are there patterns to successful biotech innovation?
Innovation in biotechnology is often portrayed as being wildly complex and unpredictable. Recent research from the Center for Integration of Science and Industry suggests that there are patterns in the timelines of technological maturation and successful development of therapeutic biotechnologies that are predictable from innovation theory.
Research: Why commercialization of gene therapy stalled
It has been 40 years since recombinant technologies first enabled consideration of gene therapy for human disease, and 30 years since the first gene therapy companies were formed. Yet, there are no gene therapies on the market in the US or EU. A recent research paper from the Center for Integration of Science and Industry explores how asynchrony between capital investments and the maturation...
Research: STEM education in business schools?
Many expert reports have addressed the critical importance of STEM professionals in the workforce of a technology-driven, global economy. These reports are largely silent on the importance of STEM education for the business professionals who are necessary partners in translating scientific discoveries into successful products and sustainable businesses. In a recent paper, Fred Ledley examined...
Research: How to educate scientifically literate business leaders
Effective business leadership increasingly requires an appreciation of the nature of technology and its economic, social and ethical consequences. Do business schools provide this? Recent research by Fred Ledley and Steven Holt explores how science education can meet the needs of business students. Listen to podcast here.
Blog: Biotech is not just for geeks
As biotechnology matures, business professionals have an increasingly important role in the industry. These individuals need to have interdisciplinary understanding of the nature of science and technology, the process of technology innovation and implementation, and the strategic role of technology in business. Fred Ledley addresses the challenges of educating scientifically literate business...
Blog: Can changes in accounting for R&D promote innovation?
Recent revisions in how R&D is represented in calculating the Gross Domestic Product (GDP) added ½ trillion dollars to measures of the US economy. Fred Ledley anticipates that similar changes in accounting standards could significantly increase the recognized value of innovation on Bentley University’s IMPACT.
Blog: Business graduates should be literate in science and energy
When business educators met with leaders from the private and public sectors at the National Academy of Science to discuss climate change education, the message from industry executives was nearly unanimous: business undergraduates and MBAs should be literate in science and energy. To address global problems of sustainability and climate change, industry does not just need scientists; it needs...
Improving the Business of Science
New Center seeks to help translate research into products. If there were a drug that could cure cancer or prevent Alzheimer’s disease, you would undoubtedly want it. But the important question is: how would such a drug be discovered and brought to market?